Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma with Topical Imiquimod
Kubicki, S.L..; Park, K.E..; Aung, P.P..; Duvic, M.
Journal of Drugs in Dermatology Jdd 18(5): 460-462
2019
ISSN/ISBN: 1545-9616 PMID: 31141854 Document Number: 17890
Primary cutaneous anaplastic large cell lymphoma (pc-ALCL) is a CD30+ subtype of cutaneous T-cell lymphoma. It typically has a very favorable prognosis; however, traditional treatment can be expensive, invasive, and associated with significant adverse events. Imiquimod is a topical toll-like receptor approved by the Food and Drug Administration (FDA) for genital warts, actinic keratosis, and primary superficial basal cell carcinoma. In previous case reports, imiquimod has been shown to be effective against pc-ALCL. We present a case of complete resolution of pc-ALCL within 8 weeks with topical imiquimod and review the current literature.
Document emailed within 1 workday
